DSIP Protocol
Delta sleep-inducing peptide studied for potential effects on sleep regulation and stress response.
- Standard dose
- 200 mcg
- Frequency
- 1× daily, subcutaneous
- Route
- subcutaneous
- Cycle
- 4–8 weeks
- Vial
- 5 mg
Evidence Level: Investigational / Theoretical
Primarily preclinical or very limited human data — mechanism-based reasoning more than a demonstrated clinical effect. Treat as investigational.
Human evidence: Older, small-scale human studies from the 1970s–1980s; modern independent trials are limited.
Animal evidence: Foundational isolation and mechanism studies from the original discovery literature.
Introduction & Mechanism of Action
Delta sleep-inducing peptide studied for potential effects on sleep regulation and stress response.
Nonapeptide first isolated from rabbit cerebral venous blood; despite the name, its actual sleep-inducing mechanism is not fully established, and modern independent research is sparse relative to its 1970s-era discovery literature.
Receptors/targets: No confirmed receptor — mechanism not fully established
Areas of Research Interest
- Sleep-regulation research
- Stress-response studies
Benefits Reported in Research
- Sleep-regulation research
- Stress-response studies
Reported Research Dosing Range
The figures below are cited from published research literature and protocol references — they describe what has been studied, not a personal prescription or instruction.
Reported range: 100–300 mcg
Reported frequency: 1× daily, subcutaneous
Reported cycle duration: 4–8 weeks
Escalation & maintenance: A dedicated weekly escalation and maintenance schedule specific to this peptide has not yet been published here — follow the dose range and frequency above, titrating conservatively from the low end, and consult a physician before adjusting.
Research Reference Data
Published research on DSIP reports administration at 100–300 mcg via subcutaneous route. The table below cites that published research — it is not an individualized instruction.
| Variant | Route | Reported frequency | Reported dose |
|---|---|---|---|
| Standard Protocol | subcutaneous | 1× daily, subcutaneous | 200 mcg |
Reconstitution Reference
Published research protocols reconstitute a 5 mg vial with 2 mL bacteriostatic water, yielding a concentration of 2.50 mg/mL. This is cited reference information, not a personalized preparation instruction — use the general research calculator below for your own reference computation.
Open the research calculator, pre-filled for DSIP →Research Protocol Timeline
A reference summary of how this compound is described across published research — formulation, reported administration, and reported cycle length.
- 01
Formulation
Supplied as a lyophilized 5 mg vial requiring reconstitution before research use.
- 02
Reconstitution Reference
Published research protocols reconstitute this vial with 2 mL bacteriostatic water to reach 2.50 mg/mL.
- 03
Reported Research Administration
Published research describes 1× daily, subcutaneous administration via subcutaneous route, at 200 mcg per administration.
- 04
Cycle Reference
Published protocols describe a cycle duration of 4–8 weeks. Consult a physician before beginning any new research cycle.
Dilution Guide
Reconstitute with 2 mL bacteriostatic water
Bacteriostatic Water (BAC Water) is the only recommended diluent. Do not dilute with sterile water, normal saline, lidocaine, or any other solution unless explicitly specified by the manufacturer.
Handling Guide
General laboratory handling practice cited for reference — not a personalized instruction. Any human use should follow the guidance of a licensed physician.
Wash hands and clean the injection site with an alcohol swab. Pinch a fold of skin and insert the needle at a 45–90° angle for standard subcutaneous injection (abdomen, thigh, or upper arm). Inject slowly, withdraw, and apply gentle pressure. Rotate injection sites to reduce irritation, and dispose of needles in an approved sharps container.
Storage
Store lyophilized (powder) vials in a freezer at -20°C, protected from light. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within the timeframe recommended in your supplier documentation — typically 2–4 weeks.
Monitoring
Monitor for injection-site reactions and the side effects listed above. Stop use and consult a physician if severe or persistent reactions occur. This is a general monitoring guideline, not a personalized medical monitoring plan.
Side Effects
- Injection-site irritation (most commonly reported)
Contraindications
- Pregnancy
Drug interactions
- Theoretical interaction with other sleep-affecting medications not well characterized
Safety
- No meaningful modern human safety database
Mechanism of action is not fully established; modern independent human trials are limited.
Expected Results & Comparison
DSIP is the peptide in this catalog most directly associated with sleep-regulation research by name, but its mechanism is not fully established and modern evidence is sparser than for many other catalog peptides — the name reflects historical framing more than a settled modern evidence base.